tiprankstipranks
Trending News
More News >
Ayr Wellness (TSE:AYR.A)
:AYR.A

Ayr Wellness (AYR.A) AI Stock Analysis

Compare
71 Followers

Top Page

TSE:AYR.A

Ayr Wellness

(AYR.A)

Select Model
Select Model
Select Model
Neutral 40 (OpenAI - 5.2)
Rating:40Neutral
Price Target:
C$0.15
▼(-8.13% Downside)
Ayr Wellness faces significant financial and operational challenges, with declining profitability, increasing debt, and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are poor with a negative P/E ratio. The recent initiation of CCAA proceedings further highlights the company's financial distress.

Ayr Wellness (AYR.A) vs. iShares MSCI Canada ETF (EWC)

Ayr Wellness Business Overview & Revenue Model

Company DescriptionAyr Wellness Inc., a vertically-integrated cannabis multi-state operator, cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. The company's cannabis and cannabis products include concentrates, edibles, and vaporizers. It also provides administrative, consulting, and operations support services to licensed cannabis companies. As of November 1, 2022, Ayr Wellness Inc. operated 52 dispensaries. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.
How the Company Makes MoneyAyr Wellness generates revenue through multiple key streams, primarily from the sale of cannabis products in both retail and wholesale markets. The company operates a network of dispensaries that sell its branded products directly to consumers, which constitutes a significant portion of its revenue. Additionally, Ayr Wellness engages in wholesale distribution to other retailers, expanding its market reach. The company also benefits from partnerships with local cultivators and suppliers, which help optimize its supply chain and reduce costs. Furthermore, revenue is bolstered by its focus on product innovation and brand development, allowing it to capture a larger share of the growing cannabis market. Regulatory compliance and strategic market positioning in key states also play a crucial role in driving sales and profitability.

Ayr Wellness Earnings Call Summary

Earnings Call Date:Mar 06, 2025
(Q4-2024)
|
% Change Since: |
Next Earnings Date:Mar 05, 2026
Earnings Call Sentiment Neutral
The call highlighted strategic moves to strengthen the business through operational streamlining and market expansion, particularly in Ohio. However, significant challenges persist, including price compression and various operational difficulties, leading to a decline in profitability and substantial impairment charges.
Q4-2024 Updates
Positive Updates
Strong Wholesale Revenue Growth
CPG wholesale revenue in 2024 was up 20% year-over-year, with core brands Kynd, Haze, and Later Days up 126% over the prior year.
Ohio Market Expansion
Ohio adult use sales in Q4 contributed to meaningful increases in both retail and wholesale revenues. Ohio retail sales increased 41% quarter-over-quarter.
Operational Streamlining
Efforts to streamline operations include selling assets in Illinois, consolidating facilities in Nevada and Massachusetts, and reducing SG&A costs.
New Indoor Cultivation Facility in Florida
Launch of a new indoor cultivation facility in Ocala, expected to come online in Q2, will more than double current flower production capacity.
Negative Updates
Price Compression Across Various Markets
Price compression continued to impact margins, with BDSA flower pricing decreasing sequentially across all markets, ranging from 5% to 12%.
Challenges in Florida
Florida faced price compression, seasonal greenhouse impacts, and inventory challenges stemming from the transition to a new seed-to-sale tracking system.
Q4 Gross Profit Decline
Q4 gross profit of $35.8 million represented a 17% decrease from the prior quarter and a 27% decrease from the prior year.
Impairment Charges
Q4 loss from continuing operations was $133.9 million, driven by $116 million of non-cash impairment charges, including a $94 million goodwill impairment.
Company Guidance
During the Ayr Wellness fourth quarter and full-year 2024 earnings call, Interim CEO Steven Cohen and President George DeNardo discussed the company's strategic focus on sustainable growth and profitability amidst industry challenges. The call highlighted that full-year sales remained flat at $463.6 million compared to the previous year, with retail sales declining by 4% and wholesale sales increasing by 28%. Adjusted gross margin was reported at 51.6%, down from 55% the previous year, primarily due to price compression and a shift in revenue from retail to wholesale. Ayr emphasized its commitment to core markets, including Florida, Ohio, and Pennsylvania, and announced plans to divest non-core assets like those in Illinois. The $10 million CapEx guidance for 2025, excluding potential Virginia investments, reflects a careful approach to capital deployment. Ayr's leadership transition includes the upcoming departure of CFO Brad Asher, with a focus on building a resilient leadership team to drive future success.

Ayr Wellness Financial Statement Overview

Summary
Ayr Wellness is experiencing financial challenges, with declining profitability, increasing debt levels, and negative cash flows. The company needs to improve operational efficiency and manage its leverage to stabilize its financial position.
Income Statement
Ayr Wellness has faced declining profitability with negative EBIT and net income over the recent years. Revenue has been stagnant, and margins, including gross profit, have decreased. The company shows no revenue growth and negative EBIT and EBITDA margins, indicating operational inefficiencies.
Balance Sheet
The balance sheet shows a reasonable equity ratio, but the debt-to-equity ratio has been increasing, indicating rising leverage. The return on equity is negative due to ongoing losses, which suggests potential financial instability.
Cash Flow
Cash flow is a concern with negative free cash flow and declining operating cash flow. The operating cash flow to net income ratio is weak, and the company struggles to generate cash from its operations, raising liquidity risks.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue452.90M463.63M463.63M465.62M357.61M155.11M
Gross Profit158.83M176.68M202.44M190.44M138.10M103.10M
EBITDA-96.32M-154.53M84.60M-67.66M87.69M17.21M
Net Income-310.37M-359.31M-272.43M-245.47M-16.95M-176.33M
Balance Sheet
Total Assets1.26B1.27B1.46B1.76B1.86B615.87M
Cash, Cash Equivalents and Short-Term Investments37.64M35.48M50.77M80.64M154.34M127.24M
Total Debt634.32M621.88M597.77M621.66M483.82M190.62M
Total Liabilities946.67M904.31M889.20M928.56M839.85M465.01M
Stockholders Equity324.33M379.53M581.78M833.32M1.02B150.86M
Cash Flow
Free Cash Flow-9.58M-15.14M-12.44M-96.66M-127.78M21.74M
Operating Cash Flow11.68M9.63M27.16M-34.16M-27.78M36.51M
Investing Cash Flow-18.34M-21.81M-24.15M-66.50M-219.63M-62.25M
Financing Cash Flow-26.90M-3.10M-32.89M26.96M274.51M144.57M

Ayr Wellness Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.16
Price Trends
50DMA
0.15
Positive
100DMA
0.16
Negative
200DMA
0.19
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
29.79
Positive
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AYR.A, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.15, and below the 200-day MA of 0.19, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 29.79 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AYR.A.

Ayr Wellness Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
C$2.64B44.132.42%6.18%-28.69%
60
Neutral
C$2.30B-12.28-9.95%4.27%3.41%
58
Neutral
C$2.74B-7.29-27.61%-3.38%-31.35%
52
Neutral
C$778.61M-8.47-11.79%-6.48%22.63%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
C$2.17B-4.68-33.01%-4.58%-141.91%
40
Neutral
$18.10M-0.040.63%-31.86%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:AYR.A
Ayr Wellness
0.16
-0.53
-77.21%
TSE:CURA
Curaleaf Holdings
3.55
1.50
73.17%
TSE:GTII
Green Thumb Industries
11.39
0.94
9.00%
TSE:TRUL
Trulieve Cannabis
12.03
4.67
63.45%
TSE:CL
Cresco Labs
1.75
0.43
32.58%
TSE:VRNO
Verano Holdings
6.32
0.00
0.00%

Ayr Wellness Corporate Events

Business Operations and StrategyLegal Proceedings
AYR Wellness Initiates CCAA Proceedings Amid Restructuring Efforts
Negative
Nov 17, 2025

AYR Wellness Inc. has initiated proceedings under the Companies’ Creditors Arrangement Act in Canada as part of its restructuring efforts. This move is aligned with a previously disclosed Restructuring Support Agreement, which involves transitioning core assets to a new acquisition vehicle owned by senior noteholders. The restructuring process includes a court-supervised wind-down of AYR’s corporate parent entity and the appointment of a licensed insolvency trustee to ensure operational stability. Additionally, the company has executed a Master Purchase Agreement to transfer assets and equity interests of subsidiaries in several states to the new entity, subject to regulatory approvals.

The most recent analyst rating on ($TSE:AYR.A) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.

Business Operations and StrategyM&A Transactions
AYR Wellness Completes Auction, Initiates Core Asset Sale
Neutral
Nov 11, 2025

AYR Wellness has announced the successful completion of a public foreclosure auction, resulting in its senior noteholders acquiring core assets through a new acquisition vehicle. This marks a significant milestone in AYR’s restructuring process, as the company prepares to transfer ownership of its core assets to the new entity and wind down its existing corporate structure. The company plans to continue operating its core assets while seeking necessary regulatory approvals and maintaining its commitment to delivering high-quality products and services.

The most recent analyst rating on ($TSE:AYR.A) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.

Business Operations and StrategyLegal ProceedingsPrivate Placements and Financing
AYR Wellness Initiates Article 9 Proceedings in Debt Restructuring
Neutral
Oct 13, 2025

AYR Wellness has announced the commencement of Article 9 proceedings as part of its debt restructuring process with senior noteholders. This phase involves a foreclosure sale of certain assets and equity interests in specified subsidiaries across several states, scheduled for November 10, 2025. The company will continue operations and maintain product quality during the transition of asset ownership to the successful bidder. This restructuring step is crucial for AYR’s ongoing efforts to stabilize its financial standing and maintain cooperative relations with stakeholders.

The most recent analyst rating on ($TSE:AYR.A) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 07, 2025